

Biocon Biologics Limited

CIN: U24119KA2016PLC093936

Biocon House, Tower-3,
Semicon Park Electronic City, Phase - II,
Hosur Road, Bengaluru, Karnataka 560100 IN**T** +91 080-6775 6775, **F** +91 080-6775 1030**E** contact@bioconbiologics.comwww.bioconbiologics.com

October 2, 2025

Singapore Exchange Securities Trading Limited

4 Shenton Way # 02-01

SGX Centre 2 Singapore 068807

Dear Sir/Madam,

Subject: Stock Exchange Disclosure by Biocon Limited dated October 1, 2025

Please find attached the Stock Exchange Disclosure submitted by Biocon Limited to BSE and NSE at India, under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Kindly take the same on record and acknowledge.

Thanking you

Your faithfully

For Biocon Biologics Limited

**Akhilesh
Nand** Digitally signed by
Akhilesh Nand
Date: 2025.10.02
13:36:53 +05'30'

Akhilesh Nand

Company Secretary

Membership No. ACS 13669

Encl: as above



Biocon Limited
20th KM, Hosur Road
Electronic City
Bangalore 560 100, India
T: 91 80 2808 2808
F: 91 80 2852 3423

CIN: L24234KA1978PLC003417

www.biocon.com

BIO/SECL/EA/2025-26/99

October 01, 2025

To, The Manager BSE Limited Department of Corporate Services Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001	To, The Manager National Stock Exchange of India Limited Corporate Communication Department Exchange Plaza, Bandra Kurla Complex Mumbai – 400 050
Scrip Code – 532523	Scrip Symbol – BIOCON

Dear Sir/Madam,

Subject: Outcome of Board Meeting

Ref: Disclosure under Regulation 30 of the SEBI Listing Regulations, 2015

Further to our intimation dated September 28, 2025 under Regulation 29(1)(h) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations, 2015"), please be informed that the Board of Directors of the Company at its meeting held today i.e. on October 01, 2025, has approved the early full redemption of 1,07,000 (One Lakh Seven Thousand) unlisted, secured, rated, redeemable, Non-Convertible Debentures (NCDs) of face value of INR 1,00,000/- (Rupees One Lakh only) each, aggregating to Rs. 1,070 Crores (One Thousand and Seventy Crores only), issued and allotted by the Company on private placement basis on February 21, 2023.

Further, please be informed that the Company has made payment of due consideration today as per agreement with concerned debenture holders and the debenture trustee towards the aforesaid early full redemption of the NCDs.

The above information will also be available on the website of the Company at www.biocon.com.

The Board Meeting commenced at 6:30 P.M. (IST) and concluded at 6:48 P.M. (IST).

Kindly take the above information on record and acknowledge.

Thanking You,

Yours faithfully,

For **Biocon Limited**

RAJESH U
SHANOEY
Digitally signed
by RAJESH U
SHANOEY
Date: 2025.10.01
20:00:50 +05'30'

Rajesh U. Shanoy
Company Secretary and Compliance officer
ICSI Membership Number: A16328